Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective

Tonika Bohnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ian E. Templeton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Heidi J. Einolf, Jan L. Wahlstrom(Merck & Co., Inc., Rahway, NJ, USA (United States)), Aarti Patel(Mortimer Market Centre), Robert L. Walsky(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dieter Lang(Merck & Co., Inc., Rahway, NJ, USA (United States)), C. Lu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sirimas Sudsakorn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ralph A. Stearns(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wanping Geng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Y.-H. Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Sinz(Rutgers, The State University of New Jersey), David D. Moore(University of California, Berkeley), Liying He(Guangzhou University of Chinese Medicine), Louis Leung(Merck & Co., Inc., Rahway, NJ, USA (United States)), Susanna Tse(Merck & Co., Inc., Rahway, NJ, USA (United States)), R. Narayanan(Merck & Co., Inc., Rahway, NJ, USA (United States))
Drug Metabolism and Disposition
April 7, 2016
Cited by 110


Related Papers